Zions Bancorporation National Association UT Has $9.51 Million Stock Position in Johnson & Johnson $JNJ

Zions Bancorporation National Association UT reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 23.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 45,934 shares of the company’s stock after selling 13,696 shares during the period. Johnson & Johnson makes up approximately 0.4% of Zions Bancorporation National Association UT’s holdings, making the stock its 29th biggest holding. Zions Bancorporation National Association UT’s holdings in Johnson & Johnson were worth $9,506,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. RM Financial Services LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth approximately $401,000. J.Safra Asset Management Corp raised its holdings in Johnson & Johnson by 426.6% during the 4th quarter. J.Safra Asset Management Corp now owns 3,797 shares of the company’s stock worth $786,000 after buying an additional 3,076 shares during the period. GWN Securities Inc. raised its holdings in Johnson & Johnson by 3.9% during the 4th quarter. GWN Securities Inc. now owns 26,663 shares of the company’s stock worth $5,518,000 after buying an additional 1,005 shares during the period. Paragon Private Wealth Management LLC raised its holdings in Johnson & Johnson by 5.8% during the 4th quarter. Paragon Private Wealth Management LLC now owns 7,378 shares of the company’s stock worth $1,527,000 after buying an additional 404 shares during the period. Finally, Red Cedar Investment Management LLC raised its holdings in Johnson & Johnson by 211.2% during the 4th quarter. Red Cedar Investment Management LLC now owns 16,462 shares of the company’s stock worth $3,407,000 after buying an additional 11,172 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $238.88 on Thursday. Johnson & Johnson has a 1-year low of $149.04 and a 1-year high of $251.71. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The firm has a fifty day simple moving average of $231.70 and a 200 day simple moving average of $226.87. The stock has a market capitalization of $575.04 billion, a PE ratio of 27.62, a P/E/G ratio of 2.32 and a beta of 0.26.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The business had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. During the same period last year, the business earned $2.77 earnings per share. The firm’s revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, research analysts expect that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were paid a $1.34 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend was Tuesday, May 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 61.97%.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson announced a $1 billion acquisition of Firefly Bio, strengthening its oncology pipeline with degrader-antibody conjugate technology aimed at KRAS-driven cancers. Johnson And Johnson Buys Firefly Bio To Deepen Oncology Growth Story
• Positive Sentiment: J&J reported promising Phase 2/3 results for IMAAVY (nipocalimab-aahu) in warm autoimmune hemolytic anemia, showing durable hemoglobin response and rapid onset of effect, which could expand the company’s immunology franchise. IMAAVY Phase 2/3 Study Results
• Positive Sentiment: Erste Group raised its FY2027 EPS estimate for Johnson & Johnson, signaling confidence in the company’s longer-term earnings power. Johnson & Johnson stock page
• Positive Sentiment: Jim Cramer and other commentators highlighted J&J’s “great new drug profits” and strong balance sheet, reinforcing the stock’s defensive appeal and quality profile. Jim Cramer Applauds Johnson & Johnson’s “Great New Drug Profits, Triple-A Balance Sheet”
• Neutral Sentiment: J&J CEO Joaquin Duato said a cure for certain cancers is a realistic goal over the next decade, underscoring long-term ambition but offering no immediate financial impact. Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal
• Negative Sentiment: A Los Angeles jury awarded $32 million in a talc-related asbestos trial, keeping Johnson & Johnson’s litigation risk in focus and potentially limiting upside. Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial
• Negative Sentiment: Separate coverage of the talc verdict and broader legal risk suggests investors still have to balance J&J’s growth pipeline against ongoing liability concerns. Talc Verdict Tests Johnson & Johnson Balance Of Legal Risk And Growth

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on JNJ. Raymond James Financial lifted their price objective on shares of Johnson & Johnson from $237.00 to $258.00 and gave the company an “outperform” rating in a report on Wednesday, April 15th. Leerink Partners upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price objective on the stock in a report on Wednesday, May 13th. HSBC lifted their price objective on shares of Johnson & Johnson from $265.00 to $280.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Argus lifted their price objective on shares of Johnson & Johnson from $240.00 to $275.00 and gave the company a “buy” rating in a report on Thursday, April 16th. Finally, Stifel Nicolaus lifted their price objective on shares of Johnson & Johnson from $220.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, April 15th. Twenty analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $253.04.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.